Related Experiment Video
Updated: Aug 7, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung
Bingxue Wang1, Yang Yao1, Zhangxuan Chen1
1Department of Respiratory and Critical Care Medicine, Jinling Hospital,Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard of care for advanced non-small cell lung cancer (NSCLC). However, their comparative efficacy and safety profile in early-stage versus advanced-stage disease remains systematically unexplored.
Methods:
We performed a systematic review and meta-analysis of PubMed, Embase, Cochrane Library, and Web of Science through January 4, 2025. Included studies reported objective response rate (ORR), disease control rate (DCR), or treatment-related adverse events (TRAEs) for EGFR-TKI monotherapy. Pooled estimates were synthesized using a generalized linear mixed model (GLMM).
Results:
Forty-two studies comprising 46 treatment groups and 3713 patients (343 early-stage; 3370 advanced-stage) were included.
Efficacy:
The pooled ORR was significantly higher in advanced-stage NSCLC (0.59, 95% CI 0.51-0.67) than in early-stage disease (0.36, 95% CI 0.15-0.63). In contrast, early-stage disease achieved a higher DCR (0.95 vs. 0.89).
Safety:
Early-stage patients experienced a significantly lower incidence of Grade ≥3 TRAEs compared to those with advanced disease (8.0% vs. 21%).
Conclusion:
EGFR-TKIs provide superior tumor shrinkage (ORR) in advanced NSCLC, the reasons remain uncertain, whereas early-stage disease achieves better disease stability (DCR) with significantly enhanced tolerability. These findings suggest that stage-specific strategies-potentially combining TKIs with other modalities in early stages-are necessary to optimize clinical outcomes.
Insights
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show higher tumor shrinkage in advanced non-small cell lung cancer (NSCLC) but better disease control and tolerability in early-stage NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard for advanced non-small cell lung cancer (NSCLC).
- Comparative efficacy and safety of EGFR-TKIs in early-stage vs. advanced-stage NSCLC are not well-established.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of EGFR-TKI monotherapy in early-stage versus advanced-stage NSCLC.
- To compare objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) between disease stages.
Main Methods:
- Systematic review and meta-analysis of four major databases (PubMed, Embase, Cochrane Library, Web of Science) through January 4, 2025.
- Inclusion of 42 studies with 3713 patients (343 early-stage, 3370 advanced-stage) receiving EGFR-TKI monotherapy.
- Pooled estimates synthesized using a generalized linear mixed model (GLMM).
Main Results:
- Advanced-stage NSCLC demonstrated a significantly higher pooled ORR (0.59) compared to early-stage disease (0.36).
- Early-stage NSCLC achieved a higher DCR (0.95) than advanced-stage disease (0.89).
- Grade ≥3 TRAEs were significantly lower in early-stage patients (8.0%) versus advanced-stage patients (21%).
Conclusions:
- EGFR-TKIs yield superior tumor shrinkage (ORR) in advanced NSCLC, with higher disease stability (DCR) and tolerability in early-stage NSCLC.
- Stage-specific treatment strategies, potentially combining EGFR-TKIs with other therapies in early stages, are suggested for optimizing outcomes.
- Further research is needed to understand the reasons for differential efficacy and to develop tailored approaches for NSCLC based on disease stage.
